Single cell correlation analysis of liquid and solid biopsies in metastatic colorectal cancer.
circulating tumor cells
cytomorphology
liquid biopsy
metastatic colorectal cancer
single cell analysis
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
17 Dec 2019
17 Dec 2019
Historique:
received:
10
07
2019
accepted:
24
09
2019
entrez:
7
1
2020
pubmed:
7
1
2020
medline:
7
1
2020
Statut:
epublish
Résumé
As cancer care is transitioning to personalized therapies with necessary complementary or companion biomarkers there is significant interest in determining to what extent non-invasive liquid biopsies reflect the gold standard solid biopsy. We have established an approach for measuring patient-specific circulating and solid cell concordance by introducing tumor touch preparations to the High-Definition Single Cell Analysis workflow for high-resolution cytomorphometric characterization of metastatic colorectal cancer (mCRC). Subgroups of cells based on size, shape and protein expression were identified in both liquid and solid biopsies, which overall displayed high inter- and intra- patient pleomorphism at the single-cell level of analysis. Concordance of liquid and solid biopsies was patient-dependent and between 0.1-0.9. Morphometric variables displayed particularly high correlation, suggesting that circulating cells do not represent distinct subpopulations from the solid tumor. This was further substantiated by significant decrease in concentration of circulating cells after mCRC resection. Combined with the association of circulating cells with tumor burden and necrosis of hepatic lesions, our overall findings demonstrate that liquid biopsy cells can be informative biomarkers in the mCRC setting. Patient-specific level of concordance can readily be measured to establish the utility of circulating cells as biomarkers and define biosignatures for liquid biopsy assays.
Identifiants
pubmed: 31903162
doi: 10.18632/oncotarget.27271
pii: 27271
pmc: PMC6925029
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7016-7030Informations de copyright
Copyright: © 2019 Gerdtsson et al.
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST P. Kuhn received stock and dividends, Epic Sciences, Inc. Epic Sciences is evaluating the feasibility of translating the circulating tumor cell (CTC) assay into a commercial format. K. Bethel stock and ownership Interests, Epic Sciences, Inc.; A. Kolatkar stock and ownership interests, Epic Sciences, Inc.; James Hicks, Clinical Advisory Board, Epic Sciences, Inc.
Références
Sci Rep. 2014 Dec 19;4:7558
pubmed: 25523357
Oncotarget. 2018 Jun 29;9(50):29403-29413
pubmed: 30034626
Phys Biol. 2015 Jan 09;12(1):016008
pubmed: 25574741
Ann Surg Oncol. 2016 Jul;23(7):2168-75
pubmed: 26714949
Converg Sci Phys Oncol. 2018 Mar;4(1):
pubmed: 32670616
Cancer Res. 2013 May 1;73(9):2760-9
pubmed: 23447576
Arch Pathol Lab Med. 2009 Sep;133(9):1468-71
pubmed: 19722757
Nat Protoc. 2012 May 03;7(6):1024-41
pubmed: 22555242
JAMA Oncol. 2016 Nov 01;2(11):1441-1449
pubmed: 27262168
Oncotarget. 2016 Sep 13;7(37):59058-59069
pubmed: 27340863
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
PLoS One. 2015 Apr 24;10(4):e0123976
pubmed: 25909322
J Oncol. 2010;2010:861341
pubmed: 20111743
PLoS One. 2016 May 16;11(5):e0155126
pubmed: 27182774
J Clin Oncol. 2007 Oct 10;25(29):4575-80
pubmed: 17925551
Am J Transl Res. 2016 Oct 15;8(10):4233-4241
pubmed: 27830007
Arch Pathol Lab Med. 2018 Feb;142(2):198-207
pubmed: 29144792
Clin Transl Med. 2017 Dec 28;6(1):46
pubmed: 29285690
J Thorac Oncol. 2014 Aug;9(8):1111-9
pubmed: 25157764
J Thorac Oncol. 2018 Sep;13(9):1248-1268
pubmed: 29885479
Converg Sci Phys Oncol. 2018 Mar;4(1):
pubmed: 30906572
PLoS One. 2014 Aug 01;9(8):e101777
pubmed: 25084170
J Clin Oncol. 2009 Apr 10;27(11):1829-35
pubmed: 19273699
Cancer Treat Rev. 2018 Nov;70:1-8
pubmed: 30053724
J Thorac Oncol. 2018 Nov;13(11):1705-1716
pubmed: 30121392
Cancer Res. 2018 Aug 15;78(16):4731-4744
pubmed: 29915159
Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8549-56
pubmed: 16361536
Br J Cancer. 2011 Mar 15;104(6):1000-6
pubmed: 21364588
BMC Cancer. 2018 Feb 15;18(1):191
pubmed: 29448920
Phys Biol. 2012 Feb;9(1):016003
pubmed: 22306768
J Oncol. 2010;2010:617421
pubmed: 20016752